tradingkey.logo
tradingkey.logo

Integra Lifesciences Holdings Corp

IART
View Detailed Chart
9.200USD
-0.180-1.92%
Close 03/27, 16:00ETQuotes delayed by 15 min
493.97MMarket Cap
LossP/E TTM

Integra Lifesciences Holdings Corp

9.200
-0.180-1.92%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.92%

5 Days

+2.91%

1 Month

-19.16%

6 Months

-30.30%

Year to Date

-25.93%

1 Year

-57.58%

View Detailed Chart

Key Insights

Integra Lifesciences Holdings Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 76 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 16.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Integra Lifesciences Holdings Corp's Score

Industry at a Glance

Industry Ranking
76 / 208
Overall Ranking
196 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Integra Lifesciences Holdings Corp Highlights

StrengthsRisks
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Fairly Valued
The company’s latest PE is -1.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.73M shares, decreasing 25.06% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 341.46K shares of this stock.

Analyst Rating

Based on 11 analysts
Hold
Current Rating
16.333
Target Price
+74.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Integra Lifesciences Holdings Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Integra Lifesciences Holdings Corp Info

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Ticker SymbolIART
CompanyIntegra Lifesciences Holdings Corp
CEOPoul (Mojdeh)
Websitehttps://www.integralife.com/
KeyAI